Clinical and economic burden of extra-articular manifestations in ankylosing spondylitis patients treated with anti-tumor necrosis factor agents

References

• Elewaut D, Matucci-Cerinic M. Treatment of ankylosing spondylitis and extra-articular manifestations in everyday rheumatology practice. Rheumatology (Oxf) 2009;48:1029-35
   PubMed Web of Science ®Google Scholar
• Son JH, Cha SW. Anti-TNF-alpha therapy for ankylosing spondylitis. Clin Orthop Surg 2010;2:28-33
   PubMedGoogle Scholar
• Mielants H, Van den BF. Extra-articular manifestations. Clin Exp Rheumatol 2009;27(Suppl. 55):S56-S61
   Google Scholar
• Hamideh F, Prete PE. Ophthalmologic manifestations of rheumatic diseases. Semin Arthritis Rheum 2001;30:217-41
   PubMed Web of Science ®Google Scholar
• Rosenbaum JT, Smith JR. Anti-TNF therapy for eye involvement in spondyloarthropathy. Clin Exp Rheumatol 2002;20(Suppl. 28):S143-S145
   Google Scholar
• Braun J, Baraliakos X, Listing J, et al. Differences in the incidence of flares or new onset of inflammatory bowel diseases in patients with ankylosing spondylitis exposed to therapy with anti-tumor necrosis factor alpha agents. Arthritis Rheum 2007;57:639-47
   PubMed Web of Science ®Google Scholar
• Brandt J, Sieper J, Braun J. [Treatment of ankylosing spondylitis and undifferentiated spondyloarthritis with TNF alpha-antagonists]. Z Rheumatol 2003;62:218-27
   PubMed Web of Science ®Google Scholar
• Davis JC, Jr van der Heijde DM, Braun J, et al. Efficacy and safety of up to 192 weeks of etanercept therapy in patients with ankylosing spondylitis. Ann Rheum Dis 2008;67:346-52
   PubMed Web of Science ®Google Scholar
• van der HD, Kivitz A, Schiff MH, et al. Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2006;54:2136-46
   PubMedGoogle Scholar
• Gorman JD, Sack KE, Davis JC Jr. Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha. N Engl J Med 2002;346:1349-56
   PubMed Web of Science ®Google Scholar
• Inman RD, Davis JC, Jr Heijde D, et al. Efficacy and safety of golimumab in patients with ankylosing spondylitis: results of a randomized, double-blind, placebo-controlled, phase III trial. Arthritis Rheum 2008;58:3402-12
   PubMed Web of Science ®Google Scholar
• Kremer J, Ritchlin C, Mendelsohn A, et al. Golimumab, a new human anti-tumor necrosis factor alpha antibody, administered intravenously in patients with active rheumatoid arthritis: forty-eight-week efficacy and safety results of a phase III randomized, double-blind, placebo-controlled study. Arthritis Rheum 2010;62:917-28
   PubMed Web of Science ®Google Scholar
• Braun J, Baraliakos X, Listing J, et al. Persistent clinical efficacy and safety of anti-tumour necrosis factor alpha therapy with infliximab in patients with ankylosing spondylitis over 5 years: evidence for different types of response. Ann Rheum Dis 2008;67:340-5
   PubMed Web of Science ®Google Scholar
• Grinblat B, Scheinberg M. The enigmatic development of psoriasis and psoriasiform lesions during anti-TNF therapy: a review. Semin Arthritis Rheum 2008;37:251-5
   PubMed Web of Science ®Google Scholar
• Guignard S, Gossec L, Salliot C, et al. Efficacy of tumour necrosis factor blockers in reducing uveitis flares in patients with spondylarthropathy: a retrospective study. Ann Rheum Dis 2006;65:1631-4
   PubMed Web of Science ®Google Scholar
• Rudwaleit M, Rodevand E, Holck P, et al. Adalimumab effectively reduces the rate of anterior uveitis flares in patients with active ankylosing spondylitis: results of a prospective open-label study. Ann Rheum Dis 2009;68:696-701
   PubMed Web of Science ®Google Scholar
• Braun J, Sieper J. What is the most important outcome parameter in ankylosing spondylitis? Rheumatology (Oxf) 2008;47:1738-40
   PubMedGoogle Scholar
• Sieper J, Koenig A, Baumgartner S, et al. Analysis of uveitis rates across all etanercept ankylosing spondylitis clinical trials. Ann Rheum Dis 2010;69:226-9
   PubMed Web of Science ®Google Scholar
• Boonen A, van der HD, Landewe R, et al. Costs of ankylosing spondylitis in three European countries: the patient's perspective. Ann Rheum Dis 2003;62:741-7
   PubMed Web of Science ®Google Scholar
• Jewell DP, Satsangi J, Lobo A, et al. Infliximab use in Crohn's disease: impact on health care resources in the UK. Eur J Gastroenterol Hepatol 2005;17:1047-52
   PubMed Web of Science ®Google Scholar
• Lloyd A, Reeves P, Conway P, et al. Economic evaluation of etanercept in the management of chronic plaque psoriasis. Br J Dermatol 2009;160:380-6
   PubMed Web of Science ®Google Scholar
• Tsai HH, Punekar YS, Morris J, et al. A model of the long-term cost effectiveness of scheduled maintenance treatment with infliximab for moderate-to-severe ulcerative colitis. Aliment Pharmacol Ther 2008;28:1230-9
   PubMed Web of Science ®Google Scholar
• Odes S, Vardi H, Friger M, et al. Cost analysis and cost determinants in a European inflammatory bowel disease inception cohort with 10 years of follow-up evaluation. Gastroenterology 2006;131:719-28
   PubMed Web of Science ®Google Scholar
• Braun J, Baraliakos X, Listing J, et al. Decreased incidence of anterior uveitis in patients with ankylosing spondylitis treated with the anti-tumor necrosis factor agents infliximab and etanercept. Arthritis Rheum 2005;52:2447-51
   PubMed Web of Science ®Google Scholar
• Bonastre J, le Vaillant M, de Pouvourville G. The impact of research on hospital costs of care: an empirical study. Health Econ 2011;20(1):73-84
   PubMed Web of Science ®Google Scholar
• Lafuma A, Berdeaux G. Modelling lifetime cost consequences of ReSTOR in cataract surgery in four European countries. BMC Ophthalmol 2008;8:12
   PubMed Web of Science ®Google Scholar
• Losch A, Scheuerle A, Rupp V, et al. Transpalpebral measurement of intraocular pressure using the TGDc-01 tonometer versus standard Goldmann applanation tonometry. Graefes Arch Clin Exp Ophthalmol 2005;243:313-6
   PubMed Web of Science ®Google Scholar
• Martin J, Neurohr C, Bauer M, et al. [Cost of intensive care in a German hospital: cost-unit accounting based on the InEK matrix]. Anaesthesist 2008;57:505-12
   PubMed Web of Science ®Google Scholar
• Sohn S, Schoeffski O, Prinz J, et al. Cost of moderate to severe plaque psoriasis in Germany: a multicenter cost-of-illness study. Dermatology 2006;212:137-44
   PubMed Web of Science ®Google Scholar
• Calin A, Dijkmans BA, Emery P, et al. Outcomes of a multicentre randomised clinical trial of etanercept to treat ankylosing spondylitis. Ann Rheum Dis 2004;63:1594-600
   PubMed Web of Science ®Google Scholar
• Rolland N, Grandbastien B, Merle V, et al. [Cost of early management of chronic inflammatory intestinal disease]. Gastroenterol Clin Biol 1999;23:483-8
   PubMedGoogle Scholar
• Stark R, Konig HH, Leidl R. Costs of inflammatory bowel disease in Germany. Pharmacoeconomics 2006;24:797-814
   PubMed Web of Science ®Google Scholar
• van der HD, Braun J, Landewe R, et al. ASessment in Ankylosing Spondylitis (ASAS) international working group: a model for psoriatic arthritis and psoriasis? Ann Rheum Dis 2005;64(2 Suppl):ii108-9
   PubMedGoogle Scholar
• Braun J, van den Berg R, Baraliakos X, et al. 2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis 2011;70:896-904
   PubMed Web of Science ®Google Scholar
• Antoni CE, Kavanaugh A, Kirkham B, et al. Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT). Arthritis Rheum 2005;52:1227-36
   PubMed Web of Science ®Google Scholar
• Baeten D, De KF, Mielants H, et al. Ankylosing spondylitis and bowel disease. Best Pract Res Clin Rheumatol 2002;16:537-49
   PubMed Web of Science ®Google Scholar
• Brophy S, Calin A. Ankylosing spondylitis: interaction between genes, joints, age at onset, and disease expression. J Rheumatol 2001;28:2283-8
   PubMed Web of Science ®Google Scholar
• Reich K, Nestle FO, Papp K, et al. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. Lancet 2005;366:1367-74
   PubMed Web of Science ®Google Scholar
• Evans TJ, Moyes D, Carpenter A, et al. Protective effect of 55- but not 75-kD soluble tumor necrosis factor receptor-immunoglobulin G fusion proteins in an animal model of gram-negative sepsis. J Exp Med 1994;180:2173-9
   PubMed Web of Science ®Google Scholar
• Furst DE, Schiff MH, Fleischmann RM, et al. Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis). J Rheumatol 2003;30:2563-71
   PubMed Web of Science ®Google Scholar
• Scallon B, Cai A, Solowski N, et al. Binding and functional comparisons of two types of tumor necrosis factor antagonists. J Pharmacol Exp Ther 2002;301:418-26
   PubMed Web of Science ®Google Scholar
• Baeten D, van Hagen PM. Use of TNF blockers and other targeted therapies in rare refractory immune-mediated inflammatory diseases: evidence-based or rational? Ann Rheum Dis 2010;69:2067-73
   PubMed Web of Science ®Google Scholar
• Wendling D, Paccou J, Bethelot JM, Flipo RM, Guillaume-Czitrom S, Prati C, Dernis E, Direz G, Ferrazzi V, Ristori JM, CRI; New onset of uveitis during anti-tumor necrosis factor treatment for rheumatic diseases. Semin Arthritis Rheum. 2011;41(3):503-10
   PubMed Web of Science ®Google Scholar
• Le GJ, Marcelli C, Mouriaux F. [Can tumor necrosis factor inhibitors induce sclerouveitis?]. J Fr Ophtalmol 2009;32:511-6
   PubMed Web of Science ®Google Scholar
• Volpe A, Caramaschi P, Carletto A, et al. Psoriasis onset during infliximab treatment: description of two cases. Rheumatol Int 2006;26:1158-60
   PubMed Web of Science ®Google Scholar
• Wendling D, Balblanc JC, Briancon D, et al. Onset or exacerbation of cutaneous psoriasis during TNFalpha antagonist therapy. Joint Bone Spine 2008;75:315-8
   PubMed Web of Science ®Google Scholar
• Wollina U, Hansel G, Koch A, et al. Tumor necrosis factor-alpha inhibitor-induced psoriasis or psoriasiform exanthemata: first 120 cases from the literature including a series of six new patients. Am J Clin Dermatol 2008;9:1-14
   PubMed Web of Science ®Google Scholar